Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP.
Coppo P, Bubenheim M, Azoulay E, Galicier L, Malot S, Bigé N, Poullin P, Provôt F, Martis N, Presne C, Moranne O, Benainous R, Dossier A, Seguin A, Hié M, Wynckel A, Delmas Y, Augusto JF, Perez P, Rieu V, Barbet C, Lhote F, Ulrich M, Rumpler AC, de Witte S, Krummel T, Veyradier A, Benhamou Y. Coppo P, et al. Among authors: malot s. Blood. 2021 Feb 11;137(6):733-742. doi: 10.1182/blood.2020008021. Blood. 2021. PMID: 33150928 Free PMC article.
Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center.
Froissart A, Buffet M, Veyradier A, Poullin P, Provôt F, Malot S, Schwarzinger M, Galicier L, Vanhille P, Vernant JP, Bordessoule D, Guidet B, Azoulay E, Mariotte E, Rondeau E, Mira JP, Wynckel A, Clabault K, Choukroun G, Presne C, Pourrat J, Hamidou M, Coppo P; French Thrombotic Microangiopathies Reference Center. Froissart A, et al. Among authors: malot s. Crit Care Med. 2012 Jan;40(1):104-11. doi: 10.1097/CCM.0b013e31822e9d66. Crit Care Med. 2012. PMID: 21926591 Clinical Trial.
Splenectomy and/or cyclophosphamide as salvage therapies in thrombotic thrombocytopenic purpura: the French TMA Reference Center experience.
Beloncle F, Buffet M, Coindre JP, Munoz-Bongrand N, Malot S, Pène F, Mira JP, Galicier L, Guidet B, Baudel JL, Subra JF, Tanguy-Schmidt A, Pourrat J, Azoulay E, Veyradier A, Coppo P; Thrombotic Microangiopathies Reference Center. Beloncle F, et al. Among authors: malot s. Transfusion. 2012 Nov;52(11):2436-44. doi: 10.1111/j.1537-2995.2012.03578.x. Epub 2012 Mar 8. Transfusion. 2012. PMID: 22404639
Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience.
Benhamou Y, Assié C, Boelle PY, Buffet M, Grillberger R, Malot S, Wynckel A, Presne C, Choukroun G, Poullin P, Provôt F, Gruson D, Hamidou M, Bordessoule D, Pourrat J, Mira JP, Le Guern V, Pouteil-Noble C, Daubin C, Vanhille P, Rondeau E, Palcoux JB, Mousson C, Vigneau C, Bonmarchand G, Guidet B, Galicier L, Azoulay E, Rottensteiner H, Veyradier A, Coppo P; Thrombotic Microangiopathies Reference Center. Benhamou Y, et al. Among authors: malot s. Haematologica. 2012 Aug;97(8):1181-6. doi: 10.3324/haematol.2011.049676. Epub 2012 May 11. Haematologica. 2012. PMID: 22580997 Free PMC article.
High prevalence of infectious events in thrombotic thrombocytopenic purpura and genetic relationship with toll-like receptor 9 polymorphisms: experience of the French Thrombotic Microangiopathies Reference Center.
Morgand M, Buffet M, Busson M, Loiseau P, Malot S, Amokrane K, Fortier C, London J, Bonmarchand G, Wynckel A, Provôt F, Poullin P, Vanhille P, Presne C, Bordessoule D, Girault S, Delmas Y, Hamidou M, Mousson C, Vigneau C, Lautrette A, Pourrat J, Galicier L, Azoulay E, Pène F, Mira JP, Rondeau E, Ojeda-Uribe M, Charron D, Maury E, Guidet B, Veyradier A, Tamouza R, Coppo P; Thrombotic Microangiopathies Reference Center. Morgand M, et al. Among authors: malot s. Transfusion. 2014 Feb;54(2):389-97. doi: 10.1111/trf.12263. Epub 2013 May 27. Transfusion. 2014. PMID: 23711330
Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura.
Coppo P, Wolf M, Veyradier A, Bussel A, Malot S, Millot GA, Daubin C, Bordessoule D, Pène F, Mira JP, Heshmati F, Maury E, Guidet B, Boulanger E, Galicier L, Parquet N, Vernant JP, Rondeau E, Azoulay E, Schlemmer B; Réseau d'Etude des Microangiopathies Thrombotiques de l'Adulte. Coppo P, et al. Among authors: malot s. Br J Haematol. 2006 Jan;132(1):66-74. doi: 10.1111/j.1365-2141.2005.05837.x. Br J Haematol. 2006. PMID: 16371021 Free article. Review.
Human immunodeficiency virus-associated thrombotic microangiopathies: clinical characteristics and outcome according to ADAMTS13 activity.
Malak S, Wolf M, Millot GA, Mariotte E, Veyradier A, Meynard JL, Korach JM, Malot S, Bussel A, Azoulay E, Boulanger E, Galicier L, Devaux E, Eschwège V, Gallien S, Adrie C, Schlemmer B, Rondeau E, Coppo P; Réseau d'Etude des Microangiopathies Thrombotiques (TMA-Rare Diseases Reference Center). Malak S, et al. Among authors: malot s. Scand J Immunol. 2008 Sep;68(3):337-44. doi: 10.1111/j.1365-3083.2008.02143.x. Scand J Immunol. 2008. PMID: 18782260 Free article.
Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement.
Coppo P, Bengoufa D, Veyradier A, Wolf M, Bussel A, Millot GA, Malot S, Heshmati F, Mira JP, Boulanger E, Galicier L, Durey-Dragon MA, Frémeaux-Bacchi V, Ramakers M, Pruna A, Bordessoule D, Gouilleux V, Scrobohaci ML, Vernant JP, Moreau D, Azoulay E, Schlemmer B, Guillevin L, Lassoued K; Réseau d'Etude des Microangiopathies Thrombotiques de l'Adulte. Coppo P, et al. Among authors: malot s. Medicine (Baltimore). 2004 Jul;83(4):233-244. doi: 10.1097/01.md.0000133622.03370.07. Medicine (Baltimore). 2004. PMID: 15232311 Free article.
17 results